Navigation Links
Kuvan Receives Marketing Approval in the European Union
Date:12/9/2008

h is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the continued development and commercialization of Kuvan and BioMarin's other products and product candidates and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kuvan Receives Positive Opinion From CHMP for European Approval
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
4. Align Technology Receives Expanded Regulatory Approval in Japan
5. Adecco Receives Honor From Alcon Laboratories
6. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
7. EastMed Inc. receives FDA clearance to market uresta(TM) in the U.S.
8. SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
9. Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing
10. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
11. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... 2014 Xeno Diagnostics has again ... most recent COLA inspection. Xeno has met all ... healthcare accreditation organization. Accreditation is earned only by ... day-to-day operations, demonstrate continued accuracy in the performance ... laboratory survey. , While the Laboratory ...
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat ... Phase 2 study evaluating the investigational oral NK-1 ... patients with severe, chronic itch who are unresponsive ... care, including topical steroids and antihistamines. ... in Visual Analog Scale (VAS) itch score from ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Pharma AG, today,announced a substantial expansion of its ... Medical Officer and Head of Global Clinical,Development, Dr. ... Dr,Hans Rensland as Vice President Regulatory Affairs, Dr. ... Dr. Markus Vogt as Vice,President of Quality and ...
... A combination of two drugs can selectively block pain-sensing ... such as touch, according to a new study by ... suggests an improved way to treat pain from childbirth ... new treatments to help the millions of Americans who ...
... Troy J. Campione, Ph.D., Joins Solazyme Executive Team, ... Solazyme, a,bioscience company pioneering biofuels and health/wellness products ... the position of senior,vice president of business development. ... finalization of,partnership agreements and contracts with major companies. ...
Cached Biology Technology:Nitec Pharma Expands Senior Management Team 2Nitec Pharma Expands Senior Management Team 3Nitec Pharma Expands Senior Management Team 4Treatment blocks pain without disrupting other functions 2Treatment blocks pain without disrupting other functions 3Solazyme Announces New Senior Vice President of Business Development 2
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... GBIF Campaign? , Different users of the GBIF network ... of various types. Given the small size and coordination ... central activities to meet all of these needs. However, ... the GBIF network do coincide with the needs of these ...
... wont be making a stop at the Smithsonians National ... with love and romance, mating and dating at the ... encounter. Successful breeding is often much more complicated ... nature to take its course. Animals in captivity need ...
... coursing through the veins of men living in the North ... has been just published. Focusing on the Wirral in ... surnames were in existence as far back as medieval times, ... specifically linked to Scandinavian ancestry. The collaborative study, by ...
Cached Biology News:4 GBIF-endorsed campaigns underway 24 GBIF-endorsed campaigns underway 34 GBIF-endorsed campaigns underway 44 GBIF-endorsed campaigns underway 5Science, not romance, controls mating at Smithsonian's National Zoo 2Science, not romance, controls mating at Smithsonian's National Zoo 3Unravelling the Northwest's Viking past 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... apoptosis in mammalian cells. The CaspSCREEN ... simple and convenient means for detecting activation ... cells. The assay utilizes a substrate ... rhodamine 110 (D2R), a reported substrate for ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: